{"filing":{"accession_number":"0000882095-26-000028","cik":"0000882095","ticker":"GILD","company_name":"GILEAD SCIENCES, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"gild-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/gild-20260804.htm"},"events":[{"id":23792,"run_id":21519,"accession_number":"0000882095-26-000028","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Gilead Sciences announced its second quarter 2026 financial results on August 4, 2026, disclosing total revenues of $7.8 billion (10% increase YoY), diluted loss per share of $(8.45), and non-GAAP diluted loss per share of $(6.75). The press release filed as Exhibit 99.1 provides comprehensive quarterly financial results including product sales by category, gross margins, operating expenses, and updated full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and outlook.","company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24125,"accession_number":"0000882095-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Gilead Sciences announced its second quarter 2026 financial results on August 4, 2026, disclosing total revenues of $7.8 billion (10% increase YoY), diluted loss per share of $(8.45), and non-GAAP diluted loss per share of $(6.75). The press release filed as Exhibit 99.1 provides comprehensive quarterly financial results including product sales by category, gross margins, operating expenses, and updated full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:17:36.692549+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24125,"accession_number":"0000882095-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Gilead Sciences announced its second quarter 2026 financial results on August 4, 2026, disclosing total revenues of $7.8 billion (10% increase YoY), diluted loss per share of $(8.45), and non-GAAP diluted loss per share of $(6.75). The press release filed as Exhibit 99.1 provides comprehensive quarterly financial results including product sales by category, gross margins, operating expenses, and updated full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:17:36.692549+00:00","company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","filing_date":"2026-08-04"}]}